The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Serotonin receptors and heart valve disease—It was meant 2B
Open accessAbstract
Carcinoid heart disease was one of the first valvular pathologies studied in molecular detail, and early research identified serotonin produced by oncogenic enterochromaffin cells as the likely culprit in causing changes in heart valve tissue. Researchers and physicians in the mid-1960s noted a connection between the use of several ergot-derived medications with structures similar to serotonin and the development of heart valve pathologies similar to those observed in carcinoid patients. The exact serotonergic target that mediated valvular pathogenesis remained a mystery for many years until similar cases were reported in patients using the popular diet drug Fen-Phen in the late 1990s. The Fen-Phen episode sparked renewed interest in serotonin-mediated valve disease, and studies led to the identification of the 5-HT2B receptor as the likely molecular target leading to heart valve tissue fibrosis. Subsequent studies have identified numerous other activators of the 5-HT2B receptor, and consequently, the use of many of these molecules has been linked to heart valve disease. Herein, we: review the molecular properties of the 5-HT2B receptor including factors that differentiate the 5-HT2B receptor from other 5-HT receptor subtypes, discuss the studies that led to the identification of the 5-HT2B receptor as the mediator of heart valve disease, present current efforts to identify potential valvulopathogens by screening for 5-HT2B receptor activity, and speculate on potential therapeutic benefits of 5-HT2B receptor targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
Self-citationClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Transforming growth factor beta
(2011) · SpringerReference · doi:10.1007/springerreference_39918 · Cited by 1,944
Pazos, A., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Wipff, P.-J., Rifkin, D. B., Meister, J.-J., & Hinz, B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704042 · Cited by 1,346
Otto, C. M., Kuusisto, J., Reichenbach, D. D., Gown, A. M., & O'Brien, K. D. (1994) · Circulation · doi:10.1161/01.cir.90.2.844 · Cited by 1,315
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Thomson, A. W. (1994) · Cited by 1,116
Primary Structure And Functional Expression of the 5HT 3 Receptor, A Serotonin-gated Ion Channel
Maricq, A. V., Peterson, A. S., Brake, A. J., Myers, R. M., & Julius, D. (1991) · Science · doi:10.1126/science.1718042 · Cited by 979
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
Brooke, B. S., Habashi, J. P., Judge, D. P., Patel, N., Loeys, B., & Dietz, H. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706585 · Cited by 843
Pazos, A., Cortés, R., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90857-1 · Cited by 824
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
TGF-?1 and angiotensin networking in cardiac remodeling
ROSENKRANZ, S. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.04.030 · Cited by 683
ERSPAMER, V., & ASERO, B. (1952) · Nature · doi:10.1038/169800b0 · Cited by 670
Cohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T., Gamradt, M., ap Rhys, C. M., Holm, T. M., Loeys, B. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1536 · Cited by 669
Rabkin, E., Aikawa, M., Stone, J. R., Fukumoto, Y., Libby, P., & Schoen, F. J. (2001) · Circulation · doi:10.1161/hc4601.099489 · Cited by 620
Choudhary, M. S., Craigo, S., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592
Self-citationO’Brien, K. D., Reichenbach, D. D., Marcovina, S. M., Kuusisto, J., Alpers, C. E., & Otto, C. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.4.523 · Cited by 560
SERUM VASOCONSTRICTOR (SEROTONIN)
Rapport, M. M., Green, A. A., & Page, I. H. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57137-4 · Cited by 552
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479 · cited 7×
“…the NIMH Psychoactive Drug Screening Program has sought to screen large numbers of FDA-approved drugs and drug-like compounds for agonist activity at 5-HT2B receptors in order to identify drugs/chemotypes with HVD liability (Setola, Dukat et al. 2005; Roth 2007; Huang, Setola et al. 2009).”
BackgroundMethodInfluentialSelf-citationMultiplicity of mechanisms of serotonin receptor signal transduction
Raymond, J. R., Mukhin, Y. V., Gelasco, A., Turner, J., Collinsworth, G., Gettys, T. W., Grewal, J. S., & Garnovskaya, M. N. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00169-3 · Cited by 466
Possible Role of Valvular Serotonin 5-HT2B Receptors in the Cardiopathy Associated with Fenfluramine
Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J.-H., Link, J. R., Abbaszade, I., Hollis, J. M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26444-0 · Cited by 440
Aikawa, E., Whittaker, P., Farber, M., Mendelson, K., Padera, R. F., Aikawa, M., & Schoen, F. J. (2006) · Circulation · doi:10.1161/circulationaha.105.591768 · Cited by 426
Walker, G. A., Masters, K. S., Shah, D. N., Anseth, K. S., & Leinwand, L. A. (2004) · Circulation Research · doi:10.1161/01.res.0000136520.07995.aa · Cited by 400
Novaro, G. M., Tiong, I. Y., Pearce, G. L., Lauer, M. S., Sprecher, D. L., & Griffin, B. P. (2001) · Circulation · doi:10.1161/hc4301.098249 · Cited by 392
Serotonin 2B receptor is required for heart development
Nebigil, C. G., Choi, D.-S., Dierich, A., Hickel, P., Le Meur, M., Messaddeq, N., Launay, J.-M., & Maroteaux, L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9508 · Cited by 381
G-protein-coupled receptors at a glance
Kroeze, W. K., Sheffler, D. J., & Roth, B. L. (2003) · Journal of Cell Science · doi:10.1242/jcs.00902 · Cited by 380
Self-citationFibrotic Disorders Associated with Methysergide Therapy for Headache
Graham, J. R., Suby, H. I., LeCompte, P. R., & Sadowsky, N. L. (1966) · New England Journal of Medicine · doi:10.1056/nejm196602172740701 · Cited by 380
Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves.
Aikawa, E. R., Farber, M., Aikawa, M., & Schöen, F. J. (2004) · PubMed · Cited by 354
Expression of serotonin receptor mRNAs in blood vessels
Ullmer, C., Schmuck, K., Kalkman, H. O., & Lübbert, H. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00828-w · Cited by 339
Rajamannan, N. M., Subramaniam, M., Springett, M., Sebo, T. C., Niekrasz, M., McConnell, J. P., Singh, R. J., Stone, N. J., Bonow, R. O., & Spelsberg, T. C. (2002) · Circulation · doi:10.1161/01.cir.0000017435.87463.72 · Cited by 336
Aronow, W. S., Ahn, C., Kronzon, I., & Goldman, M. E. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01821-5 · Cited by 329
Serotonin Receptors – From Molecular Biology to Clinical Applications
PYTLIAK, M., VARGOVÁ, V., MECHÍROVÁ, V., & FELŠÖCI, M. (2011) · Physiological Research · doi:10.33549/physiolres.931903 · Cited by 318
O’Brien, K. D., Shavelle, D. M., Caulfield, M. T., McDonald, T. O., Olin-Lewis, K., Otto, C. M., & Probstfield, J. L. (2002) · Circulation · doi:10.1161/01.cir.0000035655.45453.d2 · Cited by 318
Soni, A. V., & Miller, S. W. (2009) · Cardiac Imaging · doi:10.1016/b978-0-323-05527-7.50013-5 · Cited by 311
5-Hydroxytryptamine receptors in the human cardiovascular system
Kaumann, A. J., & Levy, F. O. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.004 · Cited by 309
Olsson, M., Dalsgaard, C.-J., Haegerstrand, A., Rosenqvist, M., Rydén, L., & Nilsson, J. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90606-8 · Cited by 307
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Self-citationPathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More)
O’Brien, K. D. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000227513.13697.ac · Cited by 295
Roth, B. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00019-9 · Cited by 287
Self-citationAmisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
Abbas, A. I., Hedlund, P. B., Huang, X.-P., Tran, T. B., Meltzer, H. Y., & Roth, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1521-8 · Cited by 285
Self-citationMolecular Biology of Serotonin Receptors - Structure and Function at the Molecular Level
Kroeze, W., Kristiansen, K., & Roth, B. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393796 · Cited by 277
Self-citationSimmons, C. A., Grant, G. R., Manduchi, E., & Davies, P. F. (2005) · Circulation Research · doi:10.1161/01.res.0000161998.92009.64 · Cited by 274
Khan, M. A., Herzog, C. A., St. Peter, J. V., Hartley, G. G., Madlon-Kay, R., Dick, C. D., Asinger, R. W., & Vessey, J. T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391101 · Cited by 265
Long-Term Serotonin Administration Induces Heart Valve Disease in Rats
Gustafsson, B. I., Tømmerås, K., Nordrum, I., Loennechen, J. P., Brunsvik, A., Solligård, E., Fossmark, R., Bakke, I., Syversen, U., & Waldum, H. (2005) · Circulation · doi:10.1161/01.cir.0000159356.42064.48 · Cited by 257
Abramowski, D., Rigo, M., Duc, D., Hoyer, D., & Staufenbiel, M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00138-7 · Cited by 243
Mohler, E. R., Nichols, R., Harvey, W. P., Sheridan, M. J., Waller, B. F., & Waller, B. F. (1991) · Clinical Cardiology · doi:10.1002/clc.4960141210 · Cited by 242
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
Antonini, A., & Poewe, W. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70218-1 · Cited by 231
Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease?
Agmon, Y., Khandheria, B. K., Meissner, I., Sicks, J. D., O’Fallon, W. M., Wiebers, D. O., Whisnant, J. P., Seward, J. B., & Tajik, A. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01422-x · Cited by 225
Merryman, W. D., Youn, I., Lukoff, H. D., Krueger, P. M., Guilak, F., Hopkins, R. A., & Sacks, M. S. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00521.2005 · Cited by 225
Self-citationSERUM VASOCONSTRICTOR (SEROTONIN)
Rapport, M. M., Green, A. A., & Page, I. H. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57136-2 · Cited by 225
BindingDB (2011) · PubMed · doi:10.7270/q2154fjq · Cited by 224
Valvular Heart Disease in Patients Taking Pergolide
Pritchett, A. M., Morrison, J. F., Edwards, W. D., Schaff, H. V., Connolly, H. M., & Espinosa, R. E. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.12.1280 · Cited by 222
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
Self-citationRoth, B. L., Craigo, S. C., Choudhary, M. S., Uluer, A., Monsma, F. J., Shen, Y., Meltzer, H. Y., & Sibley, D. R. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38596-4 · Cited by 214
Self-citation5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics
Weiner, D. M., Burstein, E. S., Nash, N., Croston, G. E., Currier, E. A., Vanover, K. E., Harvey, S. C., Donohue, E., Hansen, H. C., Andersson, C. M., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29327-7 · Cited by 203
Balachandran, K., Sucosky, P., Jo, H., & Yoganathan, A. P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00900.2008 · Cited by 201
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.
Roth, B. L., Ciaranello, R. D., & Meltzer, H. Y. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11452-3 · Cited by 197
Self-citationNewman-Tancredi, A., Cussac, D., Quentric, Y., Touzard, M., Verrièle, L., Carpentier, N., & Millan, M. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039883 · Cited by 194
Conn, P. J., & Sanders-Bush, E. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90017-0 · Cited by 192
Nebigil, C. G., Launay, J.-M., Hickel, P., Tournois, C., & Maroteaux, L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050282397 · Cited by 183
Serotonin Mechanisms in Heart Valve Disease I
Jian, B., Xu, J., Connolly, J., Savani, R. C., Narula, N., Liang, B., & Levy, R. J. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64489-6 · Cited by 182
Biaixal Stress–Stretch Behavior of the Mitral Valve Anterior Leaflet at Physiologic Strain Rates
Grashow, J. S., Yoganathan, A. P., & Sacks, M. S. (2006) · Annals of Biomedical Engineering · doi:10.1007/s10439-005-9027-y · Cited by 181
Kursar, J. D., Nelson, D. L., Wainscott, D. B., & Baez, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09676-2 · Cited by 170
Merryman, W. D., Lukoff, H. D., Long, R. A., Engelmayr, G. C., Hopkins, R. A., & Sacks, M. S. (2007) · Cardiovascular Pathology · doi:10.1016/j.carpath.2007.03.006 · Cited by 160
Self-citationDoly, S., Valjent, E., Setola, V., Callebert, J., Hervé, D., Launay, J., & Maroteaux, L. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5723-07.2008 · Cited by 158
Self-citationRoth, B. L., Nakaki, T., Chuang, D., & Costa, E. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90244-2 · Cited by 157
Self-citationCARDIAC AND PULMONARY FIBROSIS DURING METHYSERGIDE THERAPY FOR HEADACHE
Graham, J. H. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196707000-00001 · Cited by 157
Balachandran, K., Sucosky, P., Jo, H., & Yoganathan, A. P. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090631 · Cited by 156
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 154
Huang, X., Setola, V., Yadav, P. N., Allen, J., Rogan, S. C., Hanson, B. J., Revankar, C. M., Robers, M., Doucette, C., & Roth, B. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058057 · Cited by 152
Self-citationChoi, D., & Maroteaux, L. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00695-3 · Cited by 151
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus
Weill, A., Païta, M., Tuppin, P., Fagot, J., Neumann, A., Simon, D., Ricordeau, P., Montastruc, J., & Allemand, H. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2044 · Cited by 151
Gustafsson, B. I., Hauso, Ø., Drozdov, I. A., Kidd, M. S., & Modlin, I. M. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.02.019 · Cited by 148
Drug-induced fibrotic valvular heart disease
Bhattacharyya, S., Schapira, A. H. V., Mikhailidis, D. P., & Davar, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60252-x · Cited by 147
Molecular and functional characteristics of heart-valve interstitial cells
Chester, A. H., & Taylor, P. M. (2007) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2007.2126 · Cited by 147
Drug-induced Valvulopathy: An Update
Elangbam, C. S. (2010) · Toxicologic Pathology · doi:10.1177/0192623310378027 · Cited by 146
Davies, M. J. (2000) · Springer eBooks · doi:10.1007/978-1-4471-0773-6_21 · Cited by 145
Nebigil, C. G., Jaffré, F., Messaddeq, N., Hickel, P., Monassier, L., Launay, J., & Maroteaux, L. (2003) · Circulation · doi:10.1161/01.cir.0000074224.57016.01 · Cited by 144
Ablation of Serotonin 5-HT2BReceptors in Mice Leads to Abnormal Cardiac Structure and Function
Nebigil, C. G., Hickel, P., Messaddeq, N., Vonesch, J., Douchet, M.-P., Monassier, L., György, K., Matz, R. L., Andriantsitohaina, R., Manivet, P., et al. (2001) · Circulation · doi:10.1161/01.cir.103.24.2973 · Cited by 144
Balachandran, K., Konduri, S., Sucosky, P., Jo, H., & Yoganathan, A. P. (2006) · Annals of Biomedical Engineering · doi:10.1007/s10439-006-9167-8 · Cited by 143
Ras Involvement in Signal Transduction by the Serotonin 5-HT2B Receptor
Launay, J., Birraux, G., Bondoux, D., Callebert, J., Choi, D., Loric, S., & Maroteaux, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.6.3141 · Cited by 141
PDZ-dependent Activation of Nitric-oxide Synthases by the Serotonin 2B Receptor
Manivet, P., Mouillet‐Richard, S., Callebert, J., Nebigil, C. G., Maroteaux, L., Hosoda, S., Kellermann, O., & Launay, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9324 · Cited by 141
Aikawa, E. R., Hoerstrup, S. P., Aikawa, M., Mayer, J. E., & Schöen, F. J. (2002) · PubMed · Cited by 139
The effects of cellular contraction on aortic valve leaflet flexural stiffness
Merryman, W. D., Huang, H. S., Schöen, F. J., & Sacks, M. S. (2005) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2004.11.008 · Cited by 135
Self-citationJaffré, F., Callebert, J., Sarre, A., Étienne-Selloum, N., Nebigil, C. G., Launay, J., Maroteaux, L., & Monassier, L. (2004) · Circulation · doi:10.1161/01.cir.0000139856.20505.57 · Cited by 133
Jaffré, F., Bonnin, P., Callebert, J., Debbabi, H., Setola, V., Doly, S., Monassier, L., Mettauer, B., Blaxall, B. C., Launay, J., et al. (2008) · Circulation Research · doi:10.1161/circresaha.108.180976 · Cited by 129
Self-citationTHE RELATIVE ACTIVITIES OF SOME TRYPTAMINE ANALOGUES ON THE ISOLATED RAT STOMACH STRIP PREPARATION
Vane, J. R. (1959) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1959.tb00933.x · Cited by 123
Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis
Skhirtladze, C., Distler, O., Dees, C., Akhmetshina, A., Busch, N., Venalis, P., Zwerina, J., Spriewald, B. M., Pileckytė, M., Schett, G. A., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23436 · Cited by 121
Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease
Droogmans, S., Cosyns, B., D’Haenen, H., Creeten, E., Weytjens, C., Franken, P. R., Scott, B., Schoors, D. F., Kemdem, A., Close, L., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.045 · Cited by 112
Elangbam, C. S., Job, L. E., Zadrozny, L. M., Barton, J. C., Yoon, L., Gates, L. D., & Slocum, N. (2008) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.03.005 · Cited by 110
Li, B., Zhang, S., Zhang, H., Nu, W., Cai, L., Hertz, L., & Peng, L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1306-5 · Cited by 109
Fibrosis and carcinoid syndrome: from causation to future therapy
Druce, M. R., Rockall, A., & Grossman, A. B. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.51 · Cited by 109
Pechkovsky, D. V., Scaffidi, A. K., Hackett, T., Ballard, J., Shaheen, F., Thompson, P. J., Thannickal, V. J., & Knight, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708226200 · Cited by 108
Serotonin Mechanisms in Heart Valve Disease II
Xu, J., Jian, B., Chu, R., Lu, Z., Li, Q., Dunlop, J., Rosenzweig-Lipson, S. J., McGonigle, P., Levy, R. J., & Liang, B. T. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64497-5 · Cited by 107
Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties
Hofmann, C., Penner, U., Dorow, R., Pertz, H. H., hnichen, S. J., HOROWSKI, R., Latt, K. P., Palla, D., & Schurad, B. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200603000-00005 · Cited by 106
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice
Fabre, A., Marchal-Sommé, J., Marchand-Adam, S., Quesnel, C., Borie, R., Dehoux, M., Ruffié, C., Callebert, J., Launay, J., Hénin, D., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00126907 · Cited by 106
Olsson, M., Rosenqvist, M., & Nilsson, J. Å. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90172-4 · Cited by 105
Cross-talk between 5-Hydroxytryptamine Receptors in a Serotonergic Cell Line
Tournois, C., Mutel, V., Manivet, P., Launay, J., & Kellermann, O. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17498 · Cited by 103
Samarakoon, R., Higgins, C. E., Higgins, C. E., & Higgins, P. J. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.12.006 · Cited by 102
The serotonin receptors : from molecular pharmacology to human therapeutics
Roth, B. L. (2006) · Cited by 101
Self-citationLindner, M. D., Hodges, D. B., Hogan, J. B., Orie, A. F., Corsa, J. A., Barten, D. M., Polson, C. T., Robertson, B., Guss, V. L., Gillman, K. W., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.056002 · Cited by 100
Role of Serotonin via 5-HT2B Receptors in the Reinforcing Effects of MDMA in Mice
Doly, S., Bertran‐Gonzalez, J., Callebert, J., Bruneau, A., Banas, S. M., Belmer, A., Boutourlinsky, K., Hervé, D., Launay, J., & Maroteaux, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007952 · Cited by 96
Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors
Yabanoğlu, S., Akkiki, M., Séguélas, M., Mialet‐Perez, J., Parini, A., & Pizzinat, N. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.12.019 · Cited by 89
Armbruster, B. N., & Roth, B. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400030200 · Cited by 81
Self-citationBenton, J. A., Kern, H. B., Leinwand, L. A., Mariner, P. D., & Anseth, K. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.195271 · Cited by 80
Fenfluramine-like cardiovascular side-effects of benfluorex
Boutet, K., Frachon, I., Jobic, Y., Gut‐Gobert, C., Leroyer, C., Carlhant-Kowalski, D., Sitbon, O., Simonneau, G., & Humbert, M. J. C. (2009) · European Respiratory Journal · doi:10.1183/09031936.00086308 · Cited by 79
TGF-β-regulated collagen type I accumulation: role of Src-based signals
Mishra, R., Zhu, L., Eckert, R. L., & Simonson, M. S. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00370.2006 · Cited by 78
The pathogenesis of atherosclerosis of the mitral and aortic valves
WALTON, K. W., Williamson, N., & Johnson, A. G. (1970) · The Journal of Pathology · doi:10.1002/path.1711010302 · Cited by 75
Differences in Tissue-Remodeling Potential of Aortic and Pulmonary Heart Valve Interstitial Cells
Merryman, W. D., Liao, J., Parekh, A., Candiello, J., Lin, H., & Sacks, M. S. (2007) · Tissue Engineering · doi:10.1089/ten.2006.0324 · Cited by 75
Self-citationRoth, B. L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.012 · Cited by 73
Self-citationMitogenic and secretory responses of human valve interstitial cells to vasoactive agents.
Hafizi, S., Taylor, P. M., Chester, A. H., Allen, S. P., & Yacoub, M. H. (2000) · PubMed · Cited by 69
Setola, V., Dukat, M., Glennon, R. A., & Roth, B. L. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009266 · Cited by 67
Self-citationHypercholesterolemic Aortic-Valve Disease
Rajamannan, N. M., Edwards, W. D., & Spelsberg, T. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmc031360 · Cited by 63
Monassier, L., Laplante, M., Jaffré, F., Bousquet, P., Maroteaux, L., & de Champlain, J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.105551 · Cited by 57
Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis.
Mason, J. W., Billingham, M. E., & Friedman, J. P. (1977) · Circulation · doi:10.1161/01.cir.56.5.889 · Cited by 52
Functions of serotonin in hypoxic pulmonary vascular remodeling
Esteve, J. M., Launay, J., Kellermann, O., & Maroteaux, L. (2007) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:47:1:33 · Cited by 50
Porvasnik, S., Germain, S. A., Embury, J. E., Gannon, K. S., Jacques, V., Murray, J., Byrne, B. J., Shacham, S., & Al-Mousily, F. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.165001 · Cited by 50
Long-term serotonin effects in the rat are prevented by terguride
Hauso, Ø., Gustafsson, B. I., Loennechen, J. P., Stunes, A. K., Nordrum, I. S., & Waldum, H. L. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.009 · Cited by 46
Elangbam, C. S., Lightfoot, R. M., Yoon, L., Creech, D., Geske, R. S., Crumbley, C. W., Gates, L. D., & Wall, H. G. (2005) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.4a6500.2005 · Cited by 44
Kellermann, O., Loric, S., Maroteaux, L., & Launay, J. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15519.x · Cited by 37
Roth, B. L., & Xia, Z. (2004) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v16.i4.10 · Cited by 36
Self-citationVen, F. L., Tribouilloy, C., Habib, G., Gueffet, J.-P., Maréchaux, S., Eicher, J., Blanchard-Lemoine, B., Rousseau, J., Henon, P., Jobic, Y., et al. (2010) · European Journal of Echocardiography · doi:10.1093/ejechocard/jeq172 · Cited by 35
Dose Dependency and Reversibility of Serotonin-Induced Valvular Heart Disease in Rats
Droogmans, S., Roosens, B., Cosyns, B., Degaillier, C., Hernot, S., Weytjens, C., Garbar, C., Caveliers, V., Pipeleers-Marichal, M. A., Franken, P. R., et al. (2009) · Cardiovascular Toxicology · doi:10.1007/s12012-009-9046-2 · Cited by 31
Kozikowski, A. P., Cho, S. J., Jensen, N. H., Allen, J. A., Svennebring, A. M., & Roth, B. L. (2010) · ChemMedChem · doi:10.1002/cmdc.201000186 · Cited by 28
Self-citationElangbam, C. S., Wehe, J. G., Barton, J. C., Krull, D., Nyska, A., Crabbs, T. A., & Kissling, G. E. (2006) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2006.08.001 · Cited by 26
Young, R., Khorana, N., Bondareva, T. S., & Glennon, R. A. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.09.010 · Cited by 22
Weintraub, M. (1984) · Archives of Internal Medicine · doi:10.1001/archinte.1984.00350180055008 · Cited by 1
Cited by
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2780 · Cited by 303
Fibrosis — A Common Pathway to Organ Injury and Failure
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1504848 · Cited by 284
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citation
Metadata
- Authors
- Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 132
- Issue
- 2
- Pages
- 146-157
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2085050037
- Cited by
- 252
- References
- 137
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.